Pre-treatment serum levels of interleukin-10, interleukin-12 and their ratio predict response to therapy and probability of event-free and overall survival in childhood soft tissue sarcomas, Hodgkin's lymphomas and acute lymphoblastic leukemias

Clinical Biochemistry

Volumn 42, Issue 10-11, 2009, Pages 1144-1157

  Bien, Ewa ^a   Balcerska, Anna ^a   Adamkiewicz Drozynska, Elzbieta ^a   Rapala, Malgorzata ^b   Krawczyk, Malgorzata ^a   Stepinski, Jan ^a  

^a MEDICAL UNIVERSITY OF GDANSK   (Poland)

^b T Marciniak Lower Silesia Specialist Hospital Wroclaw   (Poland)

Author keywords

Acute lymphoblastic leukemia; Children; Hodgkin's lymphoma; IL 10; IL 12; Prognostic marker; Response to therapy; Serum; Soft tissue sarcoma; Th1 Th2 balance

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CHLORMETHINE; DACARBAZINE; DOXORUBICIN; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 12P70; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADJUVANT THERAPY; ADOLESCENT; ADULT; ARTICLE; CANCER MORTALITY; CANCER RELAPSE; CANCER SURVIVAL; CHILD; CHILDHOOD CANCER; CONTROLLED STUDY; DRUG RESPONSE; EVENT FREE SURVIVAL; FEMALE; HIGH RISK PATIENT; HISTOPATHOLOGY; HODGKIN DISEASE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROBABILITY; PROGNOSIS; PROTEIN BLOOD LEVEL; SOFT TISSUE SARCOMA; SYMPTOM;

ADOLESCENT; BLOOD SEDIMENTATION; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; DISEASE-FREE SURVIVAL; FEMALE; HODGKIN DISEASE; HUMANS; INTERLEUKIN-10; INTERLEUKIN-12; L-LACTATE DEHYDROGENASE; MALE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROGNOSIS; SARCOMA; TREATMENT OUTCOME;

EID: 67349190105     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2009.04.004     Document Type: Article

References (106)

1. Seung L. Cytokines in cancer. In: Theze J. (Ed). The cytokine network and immune functions (1999), Oxford Univ. Press, New York 335-345
2. Fidler I. Angiogenesis and cancer metastasis. Cancer J. 6 (2000) 134-141
3. Parmiani G., Colombo M., and Melani C. Immunotherapy, gene therapy, cytokines and cancer. In: Theze J. (Ed). The cytokine networks and immune functions (1999), Oxford Univ, Press, New York 346-361
4. Becker Y. Molecular immunological approaches to biotherapy of human cancers-a review, hypothesis and implications. Anticancer Res. 26 (2006) 1113-1134
5. Rengarajan J., Szabo S., and Glimcher L. Transcriptional regulation of Th1/Th2 polarization. Immunol. Today 21 (2000) 479-483
6. Knutson K.L., and Disis M.L. Tumor antigen-specific T helper cells in cancer immunity and immunotherapy. Cancer Immunol. Immunother. 54 (2005) 721-728
7. Dy M., Vazques A., Bertoglio J., and Theze J. Overview: general aspects of cytokine properties and functions. In: Theze J. (Ed). The cytokine network and immune functions (1999), Oxford Univ. Press, Oxford 1-16
8. Johnson R., and Brown E. Cell-mediated immunity in host defense against infectious diseases. In: Mandell G., Bennett J., and Dolin R. (Eds). Principles and practice of infectious diseases (2000), Churchill Livingstone, Philadelphia 112-146
9. Shaker O.G., Moustafa W., Essmat S., Abdel-Halim M., and El-Komy M. The role of interleukin-12 in the pathogenesis of psoriasis. Clin. Biochem. 39 (2006) 119-125
10. Kidd P. Th1/Th2 balance: the hypothesis, its limitations, and implications for health and disease. Altern. Med. Rev. 8 (2003) 223-246
11. Kuby J., Cameron J., Todd C., and Mitchell J. Immunology. 4th ed (2000), Freeman Company, New York. Inc.
12. van Den Broek M., Bachmann M.F., Köhler G., et al. IL-4 and IL 10 antagonize IL-12-mediated protection against acute vaccinia virus infection with a limited role of IFN-gamma and nitric oxide synthetase 2. J. Immunol. 164 (2000) 371-378
13. Frassanito M.A., Cusmai A., and Dammacco F. Deregulated cytokine network and defective Th1 immune response in multiple myeloma. Clin. Exp. Immunol. 125 (2001) 190-197
14. Maggio E., van der Berg A., Diepstra A., Kluiver J., Visser L., and Poppema S. Chemokines, cytokines and their receptors in Hodgkin's lymphoma cell lines and tissues. Ann. Oncol. 13 (2002) 52-56
15. Lan Q., Zheng T., Rothman N., et al. Cytokine polymorphisms in the Th1/Th2 pathway and susceptibility to non-Hodgkin lymphoma. Blood 107 (2006) 4101-4108
16. Nishimura T., Nakui M., Sato M., et al. The critical role of Th1-dominant immunity in tumor immunology. Cancer Chemother. Pharmacol. 46 (2000) 52-61
17. Colombo M.P., and Trinchieri G. Interleukin-12 in anti-tumor immunity and immunotherapy. Cytokine Growth Factor Rev. 13 (2002) 155-168
18. Chamoto K., Kosaka A., Tsuji T., et al. The critical role of Th1/Tc1 circuit for the generation of tumor-specific CTL during tumor eradication in vivo by Th1-cell therapy. Cancer Sci. 94 (2003) 924-928
19. Nishimura T., Iwakabe K., Sekimoto M., et al. Distinct role of antigen-specific T helper type 1 (Th1) and Th2 cells in tumor eradication in vivo. J. Exp. Med. 190 (1999) 617-627
20. Nakamori M., Iwahashi M., Nakamura M., Ueda K., Zhang X., and Yamaue H. Intensification of antitumor effect by T helper 1-dominant adoptive immunogene therapy for advanced orthotopic colon cancer. Clin. Cancer Res. 9 (2003) 2357-2365
21. Chamoto K., Tsuji T., Funamoto H., et al. Potentiation of tumor eradication by adoptive immunotherapy with T-cell receptor gene-transduced T-helper type 1 cells. Cancer Res. 64 (2004) 386-390
22. Fernandez N.C., Levraud J.P., Haddada H., Perricaudet M., and Kourilsky P. High frequency of specific CD8+T cells in the tumor and blood is associated with efficient local IL-12 gene therapy of cancer. J. Immunol. 162 (1999) 609-617
23. Zitvogel L., Tahara H., Robbins P.D., et al. Cancer immunotherapy of established tumors with IL 12. Effective delivery by genetically engineered fibroblasts. J. Immunol. 155 (1995) 1393-1403
24. Nishioka Y., Hirao M., Robbins P.D., Lotze M.T., and Tahara H. Induction of systemic and therapeutic antitumor immunity using intratumoral injection of dendritic cells genetically modified to express interleukin 12. Cancer Res. 59 (1999) 4035-4041
25. Mortarini R., Borri A., Tragni G., et al. Peripheral burst of tumor specific cytotoxic T lymphocytes and infiltration of metastatic lesions by memory CD8+T cells in melanoma patients receiving interleukin 12. Cancer Res. 60 (2000) 3559-3568
26. Gollob J.A., Veenstra K.G., Parker R.A., et al. Phase I trial of concurrent twice-weekly recombinant human interleukin-12 plus low-dose IL-2 in patients with melanoma or renal cell carcinoma. J. Clin. Oncol. 21 (2003) 2564-2573
27. Moore K.W., Malefyt de Waal R., Coffman R.L., and O'Garra A. Interleukin-10 and the interleukin-10 receptor. Annu. Rev. Immunol. 19 (2001) 683-765
28. Hattori E., Okumoto K., Adachi T., et al. Possible contribution of circulating interleukin-10 (IL 10) to anti-tumor immunity and prognosis in patients with unresectable hepatocellular carcinoma. Hepatol. Res. 27 (2003) 309-314
29. Gastl G.A., Abrams J.S., Nanus D.M., et al. Interleukin-10 production by human carcinoma cell lines and its relationship to interleukin-6 expression. Int. J. Cancer 55 (1993) 96-101
30. Fujieda S., Lee K., Sunaga H., et al. Staining of interleukin-10 predicts clinical outcome in patients with nasopharyngeal carcinoma. Cancer 85 (1999) 1439-1445
31. Hatanaka H., Abe Y., Kamiya T., et al. Clinical implications of interleukin (IL)-10 induced by non-small-cell lung cancer. Ann. Oncol. 11 (2000) 815-819
32. Beck A., Pazolt D., Grabenbauer G.G., et al. Expression of cytokine and chemokine genes in Epstein-Barr virus-associated nasopharyngeal carcinoma: comparison with Hodgkin's disease. J. Pathol. 194 (2001) 145-151
33. Uwatoko N., Tokunaga T., Hatanaka H., et al. Expression of interleukin-10 is inversely correlated with distant metastasis of renal cell carcinoma. Int. J. Oncol. 20 (2002) 729-733
34. Sakamoto T., Saito H., Tatebe S., et al. Interleukin-10 expression significantly correlates with minor CD8+T-cell infiltration and high microvessel density in patients with gastric cancer. Int. J. Cancer 118 (2006) 1909-1914
35. Zhou J., Ye F., Chen H., Lv W., and Gan N. The expression of interleukin-10 in patients with primary ovarian epithelial carcinoma and in ovarian carcinoma cell lines. J. Int. Med. Res. 35 (2007) 290-300
36. Avradopoulos K., Mehta S., Blackinton D., and Wanebo H.J. Interleukin-10 as a possible mediator of immunosuppressive effect in patients with squamous cell carcinoma of the head and neck. Ann. Surg. Oncol. 4 (1997) 184-190
37. Poppema S., Potters M., Visser L., and Van den Berg A. Immune escape mechanism in Hodgkin's disease. Ann. Oncol. 9 (1998) 21-24
38. Kube D., Hua T.D., von Bonin F., et al. Effect of interleukin-10 gene polymorphisms on clinical outcome of patients with aggressive non-Hodgkin's lymphoma: an exploratory study. Clin. Cancer Res. 14 (2008) 3777-3784
39. Galizia G., Orditura M., Romano C., et al. Prognostic significance of circulating IL-10 and IL-6 serum levels in colon cancer patients undergoing surgery. Clin. Immunol. 102 (2002) 169-178
40. Mustea A., Könsgen D., Braicu E.I., et al. Expression of IL-10 in patients with ovarian carcinoma. Anticancer Res. 26 (2006) 1715-1718
41. Hsia C.Y., Huo T.I., Chiang S.Y., et al. Evaluation of interleukin-6, interleukin-10 and human hepatocyte growth factor as tumor markers for hepatocellular carcinoma. Eur. J. Surg. Oncol. 33 (2007) 208-212
42. Vassilakopoulos T., Nadali G., Angelopoulou M., et al. Serum interleukin-10 levels are an independent prognostic factor for patients with Hodgkin's lymphoma. Haematologica 86 (2001) 274-281
43. Fayad L., Keating M.J., Reuben J.M., et al. Interleukin-6 and interleukin-10 levels in chronic lymphocytic leukemia: correlation with phenotypic characteristics and outcome. Blood 97 (2001) 256-263
44. Kozlowski L., Zakrzewska I., Tokajuk P., and Wojtukiewicz M.Z. Concentration of interleukin-6 (IL 6), interleukin-8 (IL-8) and interleukin-10 (IL-10) in blood serum of breast cancer patients. Rocz. Akad. Med. Bialymst. 48 (2003) 82-84
45. Lech-Maranda E., Bienvenu J., Michallet A.S., et al. Elevated IL-10 plasma levels correlate with poor prognosis in diffuse large B-cell lymphoma. Eur. Cytokine Netw. 17 (2006) 60-66
46. De Vita F., Orditura M., Galizia G., et al. Serum interleukin-10 levels in patients with advanced gastrointestinal malignancies. Cancer 86 (1999) 1936-1943
47. Inagaki A., Ishida T., Ishii T., et al. Clinical significance of serum Th1-, Th2- and regulatory T cells-associated cytokines in adult T-cell leukemia/lymphoma: high interleukin-5 and -10 levels are significant prognostic factors. Int. J. Cancer 118 (2006) 3054-3061
48. Nacinovic-Duletic A., Stifter S., Dvornik S., Skunca Z., and Jonjic N. Correlation of serum IL-6, IL-8 and IL-10 levels with clinicopathological features and prognosis in patients with diffuse large B cell lymphoma. Int. J. Lab. Hematol. 30 (2008) 230-239
49. Ebrahimi B., Tucker S.L., Li D., Abbruzzese J.L., and Kurzrock R. Cytokines in pancreatic carcinoma correlation with phenotypic characteristics and prognosis. Cancer 101 (2004) 2727-2736
50. Shibata M., Nezu T., Kanou H., Abe H., Takekawa M., and Fukuzawa M. Decreased production of interleukin-12 and type 2 immune responses are marked in cachectic patients with colorectal and gastric cancer. J. Clin. Gastroenterol. 34 (2002) 416-420
51. Urosevic M., and Dummer R. HLA-G and IL-10 expression in human cancer-different stories with the same message. Semin. Cancer Biol. 13 (2003) 337-342
52. Tsuboi K., Miyazaki T., Nakajima M., et al. Serum interleukin-12 and interleukin-18 levels as a tumour marker in patients with esophageal carcinoma. Cancer Lett. 205 (2004) 207-214
53. Kumar R., Kamdard D., Madden L., et al. Th1/Th2 cytokine imbalance in meningioma, anaplastic astrocytoma and glioblastoma multiforme patients. Oncol. Rep. 15 (2006) 1513-1516
54. Nagai H., Miyaki D., Matsui T., et al. Th1/Th2 balance: an important indicator of efficacy for intra-arterial chemotherapy. Cancer Chemother. Pharmacol. 62 (2008) 959-963
55. Lathers D.M., Achille N.J., and Young M.R. Incomplete Th2 skewing of cytokines in plasma of patients with squamous cell carcinoma of the head and neck. Hum. Immunol. 64 (2003) 1160-1166
56. Sparano A., Lathers D.M., Achille N., Petruzzelli G.J., and Young M.R. Modulation of Th1 and Th2 cytokine profiles and their association with advanced head and neck squamous cell carcinoma. Otolaryngol. Head Neck Surg. 131 (2004) 573-576
57. Myśliwska J., Zorena K., Semetkowska-Jurkiewicz E., Rachoń D., Suchanek H., and Myśliwski A. High levels of circulating interleukin-10 in diabetic nephropathy patients. Eur. Cytokine Netw. 16 (2005) 117-122
58. Myśliwiec M., Zorena K., Balcerska A., Myśliwska J., Lipowski P., and Raczyńska K. The activity of N-acetyl-beta-d-glucosaminidase and tumor necrosis factor-alpha at early stage of diabetic retinopathy development in type 1 diabetes mellitus children. Clin. Biochem. 39 (2006) 851-856
59. Murai H., Terada A., Mizuno M., et al. IL-10 and RANTES are elevated in nasopharyngeal secretions of children with respiratory syncytial virus infection. Allergol. Int. 56 (2007) 157-163
60. Chung J.Y., Han T.H., Kim J.S., Kim S.W., Park C.G., and Hwang E.S. Th1 and Th2 cytokine levels in nasopharyngeal aspirates from children with human bocavirus bronchiolitis. J. Clin. Virol. 43 (2008) 223-225
61. Skotnicka B., and Hassmann E. Proinflammatory and immunoregulatory cytokines in the middle ear effusions. Int. J. Pediatr. Otorhinolaryngol. 72 (2008) 13-17
62. Kurzrock R. Cytokine deregulation in cancer. Biomed. Pharmacother. 55 (2001) 543-547
63. Contasta I., Pellegrini P., Berghella A.M., and Adorno D. Cell cycle control in cellular homeostasis during the immune response: interactions between Th1, Th2 cytokines, and Bcl2 and p53 molecules. Cancer Biother. Radiopharm. 16 (2001) 63-71
64. Salles G., and Coiffier B. Inherited cytokine response and risk of lymphoma. Lancet Oncol. 7 (2006) 3-4
65. Pawelec G., Zeuthen J., and Kiessling R. Escape from host antitumor immunity. Crit. Rev. Oncog. 8 (1997) 111-141
66. Dummer R., Yue F.Y., Pavlovic J., et al. Immune stimulatory potential of B7.1 and B7.2 retrovirally transduced melanoma cells: suppression by interleukin 10. Br. J. Cancer 77 (1998) 1413-1419
67. Khong H.T., and Restifo N.P. Natural selection of tumor variants in the generation of "tumor escape" phenotypes. Nat. Immunol. 3 (2002) 999-1005
68. Dukers D.F., Jaspars L.H., Vos W., et al. Quantitative immunohistochemical analysis of cytokine profiles in Epstein-Barr virus-positive and -negative cases of Hodgkin's disease. J. Pathol. 190 (2000) 143-149
69. Kebelmann-Betzing C., Körner G., Badiali L., et al. Characterization of cytokine, growth factor receptor, costimulatory and adhesion molecule expression patterns of bone marrow blasts in relapsed childhood B cell precursor all. Cytokine 13 (2001) 39-50
70. Schulz U., Munker R., Ertl B., Holler E., and Kolb H.J. Different types of human leukemias express the message for TNF-alpha and interleukin-10. Eur. J. Med. Res. 6 (2001) 359-363
71. Panoskaltsis N., Reid C.D., and Knight S.C. Quantification and cytokine production of circulating lymphoid and myeloid cells in acute myelogenous leukaemia. Leukemia 17 (2003) 716-730
72. Spellman J.E., Gollnick S.O., Zhang P.J., and Tomasi T.B. Cytokine production by human soft tissue sarcomas: implications for immunosuppression within the tumour bed. Surg. Oncol. 5 (1996) 237-244
73. Mocellin S., Wang E., and Marincola F.M. Cytokines and immune response in the tumor microenvironment. J. Immunother. 24 (2001) 392-407
74. Cortes J.E., Talpaz M., Cabanillas F., Seymour J.F., and Kurzrock R. Serum levels of interlukin-10 in patients with diffuse large cell lymphoma: lack of correlation with prognosis. Blood 85 (1995) 2516-2520
75. Silvestre J.S., Mallat Z., Tamarat R., Duriez M., Tedgui A., and Levy B.I. Regulation of matrix metalloproteinase activity in ischemic tissue by interleukin-10: role in ischemia-induced angiogenesis. Circ. Res. 89 (2001) 259-264
76. Kohno T., Mizukami H., Suzuki M., et al. Interleukin-10-mediated inhibition of angiogenesis and tumor growth in mice bearing VEGF-producing ovarian cancer. Cancer Res. 63 (2003) 5091-5094
77. De Vita F., Orditura M., Galizia G., et al. Serum interleukin-10 levels as a prognostic factor in advanced non-small cell lung cancer patients. Chest 117 (2000) 365-373
78. Chau G.Y., Wu C.W., Lui W.Y., et al. Serum interleukin-10 but not interleukin-6 is related to clinical outcome in patients with resectable hepatocellular carcinoma. Ann. Surg. 231 (2000) 552-558
79. Nemunaitis J., Fong T., Shabe P., Martineau D., and Ando D. Comparison of serum interleukin-10 (IL-10) levels between normal volunteers and patients with advanced melanoma. Cancer Invest. 19 (2001) 239-247
80. el-Far M., Fouda M., Yahya R., and el-Baz H. Serum IL-10 and IL-6 levels at diagnosis as independent predictors of outcome in non-Hodgkin's lymphoma. J. Physiol. Biochem. 60 (2004) 253-258
81. Lech-Maranda E., Baseggio L., Bienvenu J., et al. Interleukin-10 gene promoter polymorphisms influence the clinical outcome of diffuse large B-cell lymphoma. Blood 103 (2004) 3529-3534
82. Aydin F., Yilmaz M., Ozdemir F., Kavgaci H., Yavuz M.N., and Yavuz A.A. Correlation of serum IL-2, IL-6 and IL-10 levels with International Prognostic Index in patients with aggressive non-Hodgkin's lymphoma. Am. J. Clin. Oncol. 25 (2002) 570-572
83. Hensler T., Heidecke C.D., Hecker H., et al. Increased susceptibility to postoperative sepsis in patients with impaired monocyte IL-12 production. J. Immunol. 161 (1998) 2655-2659
84. Hayes M.P., Wang J., and Norcross M.A. Regulation of interleukin-12 expression in human monocytes: selective priming by interferon-g of lipopolysaccharide-inducible p35 and p40 genes. Blood 86 (1995) 646-650
85. Wigginton J.M., Kuhns D.B., Back T.C., Brunda M.J., Wiltrout R.H., and Cox G.W. Interleukin 12 primes macrophages for nitric oxide production in vivo and restores depressed nitric oxide production by macrophages from tumor-bearing mice: implications for the antitumor activity of interleukin 12 and/or interleukin 2. Cancer Res. 56 (1996) 1131-1136
86. Dobrzanski M.J., Reome J.B., and Dutton R.W. Type 1 and type 2 CD8+ effector T cell subpopulations promote long-term tumor immunity and protection to progressively growing tumor. J. Immunol. 164 (2000) 916-925
87. Kieper W.C., Prlic M., Schmidt C.S., Mescher M.F., and Jameson S.C. IL-12 enhances CD8 T cell homeostatic expansion. J. Immunol. 166 (2001) 5515-5521
88. Schmidt C.S., and Mescher M.F. Peptide antigen priming of naive, but not memory, CD8 T cells requires a third signal that can be provided by IL-12. J. Immunol. 168 (2002) 5521-5529
89. Toi M., Gion M., Saji H., et al. Endogenous interleukin 12: relationship with angiogenic factors, hormone receptors and nodal status in human breast cancinoma. Int. J. Oncol. 15 (1999) 1169-1175
90. Yao L.C., Sgadari C., Furuke K., Bloom E.T., Teruya-Feldstein J., and Tosato G. Contribution of natural killer cells to inhibition of angiogenesis by interleukin-12. Blood 93 (1999) 1612-1621
91. Zou J.P., Yamamoto N., Fujii T., et al. Systemic administration of rIL-12 induces complete tumor regression and protective immunity: response is correlated with a striking reversal of suppressed IFN-gamma production by anti-tumor T cells. Int. Immunol. 7 (1995) 1135-1145
92. Lissoni P., Mengo S., Mandala M., et al. Physiopathology of IL-12 in human solid neoplasms: blood levels of IL-12 in early or advanced cancer patients and their variations with surgery and immunotherapy. J. Biol. Regul. Homeost. Agents 12 (1998) 38-41
93. Okamoto M., Ohe G., Oshikava T., et al. Induction of cytokines and killer cell activities by cisplatin and 5-fluorouracil in head and neck cancer patients. Anticancer Drugs 11 (2000) 165-173
94. Nakayama Y., Shibao K., Sako T., et al. Serum levels of interleukin-12 in patients with gastrointestinal cancer. Anticancer Res. 20 (2000) 635-640
95. Salmaggi A., Eoli M., Frigerio S., et al. Intracavitary VEGF, βFGF, IL-8, IL-12 levels in primary and recurrent malignant glioma. J. Neurooncol. 62 (2003) 297-303
96. Jebreel A., Mistry D., Loke D., et al. Investigation of interleukin 10, 12 and 18 levels in patients with head and neck cancer. J. Laryngol. Otol. 121 (2007) 246-252
97. Lissoni P., Rovelli F., Fumagalli L., Mauri E., Barni S., and Tancini G. Increased blood concentrations of interleukin-12 are associated with a longer survival in untreatable metastatic solid tumor patients: preliminary observations. Int. J. Biol. Markers 12 (1997) 125-127
98. Lissoni P., Rovelli F., Pittalis S., et al. Interleukin-12 in early or advanced cancer patients. Eur. J. Cancer. 33 (1997) 1703-1705
99. Kovacs E. The serum levels of IL-12 and IL-16 in cancer patients. Relation to the tumour stage and previous therapy. Biomed. Pharmacother. 55 (2001) 111-116
100. Diakowska D., Markocka-Maczka K., Grabowski K., and Lewandowski A. Serum interleukin-12 and interleukin-18 levels in patients with oesophageal squamous cell carcinoma. Exp. Oncol. 28 (2006) 319-322
101. Yin Z., Braun J., Neure L., et al. Crucial role of interleukin-10/interleukin-12 balance in the regulation of the type 2 T helper cytokine response in reactive arthritis. Arthritis. Rheum. 40 (1997) 1788-1797
102. Gao J.X., Madrenas J., Zeng W., et al. CD40-deficient dendritic cells producing interleukin-10, but not interleukin-12, induce T-cell hyporesponsiveness in vitro and prevent acute allograft rejection. Immunology 98 (1999) 159-170
103. Kariya S., Okano M., Hattori H., et al. TH1/TH2 and regulatory cytokines in adults with otitis media with effusion. Otol. Neurotol. 27 (2006) 1089-1093
104. Huang M., Stolina M., Sharma S., et al. Non small cell lung cancer cyclooxygenase-2-dependent regulation of cytokine balance in lymphocytes and macrophages: up-regulation of interleukin 10 and down regulation of interleukin 12 production. Cancer Res. 58 (1998) 1208-1216
105. Łuczyński W., Stasiak-Barmuta A., Krawczuk-Rybak M., et al. Th1/Th2 balance in acute lymphoblastic leukemia in children. Przegl. Lek. 61 (2004) 919-923
106. Stolina M., Sharma S., Lin Y., et al. Specific inhibition of cyclooxygenase 2 restores antitumor reactivity by altering the balance of IL-10 and IL-12 synthesis. J. Immunol. 164 (2000) 361-370